Skip to main content
Fig.1 | Journal of Neuroinflammation

Fig.1

From: Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses

Fig.1

Clinical outcomes of the INCIDENT-MS study A CONSORT plot indicating patient groups. B Dot plot indicating duration of initiation therapy (circles), escalation therapy (boxes) and follow-up (diamonds) from relapse onset. Colours indicate different treatment groups and can be referred to throughout. C Bar graphs indicating the proportion of different relapse categories among treatment groups. Shaded boxes indicate patients who received immunoadsorption as second-escalation therapy. D EDSS scores among treatment groups at discharge (boxes) and follow-up (diamonds). E Treatment response stratified according to the matrix proposed by Conway et al. at discharge and follow-up. F Difference of the MSFC scores at discharge and follow-up compared to baseline. G Difference of SF-36 healthcare-related quality of life scores at follow-up compared to baseline. *: p < 0.05; **: p < 0.01; ***: p < 0.001; significance levels were determined using Mann–Whitney rank sum test (D; F; G) or Fisher’s exact test (E). IA immunoadsorption, MPS methylprednisolone, EDSS expanded disability status scale; MSFC multiple sclerosis functional composite, SF36 short-form 36 questionnaire

Back to article page